reaction. Accordingly, stopping the PPI will possibly decrease the symptoms within days.
The awareness for microscopic colitis has risen over the last decade following an increase in incidence rates from 4.6 to 24.7 per 100 000 person-years. 3 Unfortunately, therapeutic options are scarce; the only evidence-based treatment option is budesonide 9 mg daily. 4, 5 In recent years, several risk factors related to the development of microscopic colitis have been reported including smoking, NSAIDs and proton pump inhibitors (PPIs). A large nationwide registry study from Denmark investigated the relation between PPI use and microscopic colitis more closely. 6 Bonderup et al identified 10 652 patients with first-diagnosed microscopic colitis between 2004 and 2013. They confirmed earlier reported strong associations 7 between current PPI use and microscopic colitis incidence with an adjusted odds ratio (OR) for collagenous colitis of 6.98 (95% CI: 6.45-7.55) and for lymphocytic colitis The pathophysiological explanation for PPI-induced microscopic colitis remains unclear. Therefore, the lack of a dose-response relation is of the utmost interest. Until this paper was published, this relation was not investigated. 7 A comparison of 3 737 cases of microscopic colitis with and without current PPI use showed no increased risk of microscopic colitis with increasing PPI dose. 6 The lack of a dose-response relation suggests an idiosyncratic adverse
